PALI-2108 is the first and only PDE4 inhibitor in development targetingthe terminal ileum and colon for treatment of ulcerative colitis (UC) and ...

Maintenance therapy with subcutaneous infliximab was more effective than placebo regardless of disease location or segment ...

Carlsbad, CA, May 27, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing ...

We reviewed all colonoscopic procedures performed in the endoscopy center of Ajou University Hospital, which is a 1000-bed teaching hospital, between 1 January 2005 and 31 December 2005. Six ...

A woman, aged 61, had a colonoscopy because of a positive result from a fecal occult blood test. No abnormalities were detected in the colon but endoscopic examination of the terminal ileum showed ...

Palisade Bio's PALI-2108 could be a game-changer for gut health with strong upside potential. Read here for an investment analysis of PALI stock.

INCHEON, South Korea, Nov. 26, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that a post-hoc analysis of the LIBERTY-CD study, which showed that the efficacy of ZYMFENTRA® (infliximab-dyyb) is ...

THE small intestine comprises the longest portion of the alimentary canal and yet receives small consideration in the diagnosis of intestinal tumors. The reason is the rarity of neoplasms in the small ...

The cutaneous catheterizable ileocecocytoplasty is a surgery that we have found to be very successful here at University of Utah Health. In this surgery the bladder is expanded with large bowel from ...